This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
8 Sep 2016

Dipexium Pharmaceuticals announces issuance of Locilex patent by EU

Patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections.

Dipexium Pharmaceuticals has announced that the European Patent Office has issued a new Locilex patent in the European Union (EU). The patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections. The issued patent has an expiry date in June 2033.

"This constitutes the first patent granted by the EU, the second largest pharmaceuticals market in the world," stated David P. Luci, President and CEO of Dipexium. "This is an important building block for our commercialization strategy for Locilex in Europe." Mr Luci continued: "Dipexium now has issued patents for Locilex in the US, EU, and Japan, the three largest pharmaceuticals markets in the world, as well as Australia and New Zealand. In addition, Dipexium has obtained notice of allowance for patents in Hong Kong and Korea. We anticipate the issuance of additional patents for Locilex in other major international markets throughout 2016 and 2017."

Related News